Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 31, 2026

‘Mr. Buffett, how can I make $30 billion?’: Warren Buffett’s answer reveals his 3 simple investing rules

View original at finance.yahoo.com
‘Mr. Buffett, how can I make $30 billion?’: Warren Buffett’s answer reveals his 3 simple investing rules J. Kempin / Getty Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • He almost passed on acquiring See's Candies over a $5 million price difference, which would have cost Berkshire $1.35 billion in gains

    80% confidence
  • The best advice for investors is to get started as early as possible, using compound interest like a snowball rolling down a hill

    80% confidence
  • Small-cap stocks were around 30% cheaper than large-cap stocks as of the start of Q4 2023

    80% confidence
  • Their stock recommendations have beaten the S&P 500 by almost 12% on average across 400 stock picks over four years

    80% confidence
  • 49% of Americans say they don't invest because they don't have enough money, believing they need about $1,000 to get started

    80% confidence
  • If starting investing again today with $10,000, he would focus on smaller companies because there's more chance something is overlooked in that arena

    80% confidence
  • Success comes from being smart in specific areas and staying within those areas of competency

    80% confidence
  • The valuation gap between small-cap and large-cap stocks is near a 25-year low, suggesting potential for small-cap outperformance

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com